Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion

Eun Jee Chung, Young Taek Hong, Sungchul Lee, Oh Woong Kwon, Hyoung Jun Koh

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Purpose: To evaluate the prognostic factors for visual outcome after intravitreal bevacizumab injection to treat macular edema due to branch retinal vein occlusion (BRVO). Methods: Fifty eyes of 50 consecutive patients treated with intravitreal bevacizumab for macular edema due to BRVO with minimum follow-up of 3 months were retrospectively reviewed. Patients were categorized into two groups according to the final visual acuity. Group 1 consisted of eyes with 5 or more ETDRS letters gain, and group 2 consisted of eyes with less than 5 letters improvement or which had worsened at last follow-up visit. Comparative clinical and fluorescein angiographic characteristics were analyzed between the two groups. Results: Of 50 eyes, 28 (56%) had improved vision after intravitreal bevacizumab injections and were categorized as group 1; 22 eyes (44%) were categorized as group 2. The number of early VA gainers, who showed visual improvement at 1 month after bevacizumab injection, was significantly higher in group 1 (P < 0.001, chi-square test). The early gainers tend to maintain significantly better visual outcome until last follow-up. The number of eyes with angiographically documented macular ischemia was significantly higher in group 2 (P < 0.001). In group 2, the decrease in central macular thickness was not accompanied by visual acuity improvement. Conclusion: Preoperative presence of macular ischemia can be useful in predicting the outcome of visual acuity after intravitreal bevacizumab for macular edema due to BRVO. The early gainers who favorably responded to the initial intravitreal bevacizumab injection are most likely to benefit from the bevacizumab treatment.

Original languageEnglish
Pages (from-to)1241-1247
Number of pages7
JournalGraefe's Archive for Clinical and Experimental Ophthalmology
Volume246
Issue number9
DOIs
Publication statusPublished - 2008 Sep 1

Fingerprint

Retinal Vein Occlusion
Macular Edema
Intravitreal Injections
Visual Acuity
Ischemia
Chi-Square Distribution
Bevacizumab
Fluorescein
Injections

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

@article{39b311e752aa442ca1219585ab8a47dc,
title = "Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion",
abstract = "Purpose: To evaluate the prognostic factors for visual outcome after intravitreal bevacizumab injection to treat macular edema due to branch retinal vein occlusion (BRVO). Methods: Fifty eyes of 50 consecutive patients treated with intravitreal bevacizumab for macular edema due to BRVO with minimum follow-up of 3 months were retrospectively reviewed. Patients were categorized into two groups according to the final visual acuity. Group 1 consisted of eyes with 5 or more ETDRS letters gain, and group 2 consisted of eyes with less than 5 letters improvement or which had worsened at last follow-up visit. Comparative clinical and fluorescein angiographic characteristics were analyzed between the two groups. Results: Of 50 eyes, 28 (56{\%}) had improved vision after intravitreal bevacizumab injections and were categorized as group 1; 22 eyes (44{\%}) were categorized as group 2. The number of early VA gainers, who showed visual improvement at 1 month after bevacizumab injection, was significantly higher in group 1 (P < 0.001, chi-square test). The early gainers tend to maintain significantly better visual outcome until last follow-up. The number of eyes with angiographically documented macular ischemia was significantly higher in group 2 (P < 0.001). In group 2, the decrease in central macular thickness was not accompanied by visual acuity improvement. Conclusion: Preoperative presence of macular ischemia can be useful in predicting the outcome of visual acuity after intravitreal bevacizumab for macular edema due to BRVO. The early gainers who favorably responded to the initial intravitreal bevacizumab injection are most likely to benefit from the bevacizumab treatment.",
author = "Chung, {Eun Jee} and Hong, {Young Taek} and Sungchul Lee and Kwon, {Oh Woong} and Koh, {Hyoung Jun}",
year = "2008",
month = "9",
day = "1",
doi = "10.1007/s00417-008-0866-8",
language = "English",
volume = "246",
pages = "1241--1247",
journal = "Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie",
issn = "0065-6100",
publisher = "Springer Verlag",
number = "9",

}

Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. / Chung, Eun Jee; Hong, Young Taek; Lee, Sungchul; Kwon, Oh Woong; Koh, Hyoung Jun.

In: Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 246, No. 9, 01.09.2008, p. 1241-1247.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion

AU - Chung, Eun Jee

AU - Hong, Young Taek

AU - Lee, Sungchul

AU - Kwon, Oh Woong

AU - Koh, Hyoung Jun

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Purpose: To evaluate the prognostic factors for visual outcome after intravitreal bevacizumab injection to treat macular edema due to branch retinal vein occlusion (BRVO). Methods: Fifty eyes of 50 consecutive patients treated with intravitreal bevacizumab for macular edema due to BRVO with minimum follow-up of 3 months were retrospectively reviewed. Patients were categorized into two groups according to the final visual acuity. Group 1 consisted of eyes with 5 or more ETDRS letters gain, and group 2 consisted of eyes with less than 5 letters improvement or which had worsened at last follow-up visit. Comparative clinical and fluorescein angiographic characteristics were analyzed between the two groups. Results: Of 50 eyes, 28 (56%) had improved vision after intravitreal bevacizumab injections and were categorized as group 1; 22 eyes (44%) were categorized as group 2. The number of early VA gainers, who showed visual improvement at 1 month after bevacizumab injection, was significantly higher in group 1 (P < 0.001, chi-square test). The early gainers tend to maintain significantly better visual outcome until last follow-up. The number of eyes with angiographically documented macular ischemia was significantly higher in group 2 (P < 0.001). In group 2, the decrease in central macular thickness was not accompanied by visual acuity improvement. Conclusion: Preoperative presence of macular ischemia can be useful in predicting the outcome of visual acuity after intravitreal bevacizumab for macular edema due to BRVO. The early gainers who favorably responded to the initial intravitreal bevacizumab injection are most likely to benefit from the bevacizumab treatment.

AB - Purpose: To evaluate the prognostic factors for visual outcome after intravitreal bevacizumab injection to treat macular edema due to branch retinal vein occlusion (BRVO). Methods: Fifty eyes of 50 consecutive patients treated with intravitreal bevacizumab for macular edema due to BRVO with minimum follow-up of 3 months were retrospectively reviewed. Patients were categorized into two groups according to the final visual acuity. Group 1 consisted of eyes with 5 or more ETDRS letters gain, and group 2 consisted of eyes with less than 5 letters improvement or which had worsened at last follow-up visit. Comparative clinical and fluorescein angiographic characteristics were analyzed between the two groups. Results: Of 50 eyes, 28 (56%) had improved vision after intravitreal bevacizumab injections and were categorized as group 1; 22 eyes (44%) were categorized as group 2. The number of early VA gainers, who showed visual improvement at 1 month after bevacizumab injection, was significantly higher in group 1 (P < 0.001, chi-square test). The early gainers tend to maintain significantly better visual outcome until last follow-up. The number of eyes with angiographically documented macular ischemia was significantly higher in group 2 (P < 0.001). In group 2, the decrease in central macular thickness was not accompanied by visual acuity improvement. Conclusion: Preoperative presence of macular ischemia can be useful in predicting the outcome of visual acuity after intravitreal bevacizumab for macular edema due to BRVO. The early gainers who favorably responded to the initial intravitreal bevacizumab injection are most likely to benefit from the bevacizumab treatment.

UR - http://www.scopus.com/inward/record.url?scp=48449106803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48449106803&partnerID=8YFLogxK

U2 - 10.1007/s00417-008-0866-8

DO - 10.1007/s00417-008-0866-8

M3 - Article

VL - 246

SP - 1241

EP - 1247

JO - Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie

JF - Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie

SN - 0065-6100

IS - 9

ER -